ICA-27243
CAS No. 325457-89-4
ICA-27243 ( —— )
产品货号. M22578 CAS No. 325457-89-4
ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 is a potent and orally active KCNQ2/Q3 potassium channel opener (EC50: 0.38 μM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥583 | 有现货 |
|
10MG | ¥988 | 有现货 |
|
25MG | ¥1879 | 有现货 |
|
50MG | ¥3102 | 有现货 |
|
100MG | ¥4528 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ICA-27243
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 is a potent and orally active KCNQ2/Q3 potassium channel opener (EC50: 0.38 μM).
-
产品描述ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 is a potent and orally active KCNQ2/Q3 potassium channel opener (EC50: 0.38 μM). ICA-27243 also has antiepileptic and anticonvulsant effects. ICA-27243 increases both 86Rb+ efflux (EC50 = 0.2 μM) and whole-cell currents in Chinese hamster ovary cells stably expressing heteromultimeric KCNQ2/Q3 channels (EC50 = 0.4 μM). ICA-27243 produces membrane potential hyperpolarization that could be prevented by coadministration with the M-current inhibitors XE-991 and Linopirdine, in SH-SY5Y human neuroblastoma cells .In the mouse maximal electroshock epilepsy model, ICA-27243 (1-100 mg/kg; oral administration; male CD-1 mice) has anticonvulsant activity (ED50: 8.4 mg/kg).
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体KCNQ2/Q3 potassium channel
-
研究领域——
-
适应症——
化学信息
-
CAS Number325457-89-4
-
分子量268.65
-
分子式C12H7ClF2N2O
-
纯度>98% (HPLC)
-
溶解度DMSO:247 mg/mL (919.41mM; Need ultrasonic)
-
SMILESFc1ccc(cc1F)C(=O)Nc1ccc(Cl)nc1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wickenden AD, et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol. 2008 Mar;73(3):977-86.
产品手册
关联产品
-
2,2,2-Trichloroethan...
2,2,2-Trichloroethanol is an agonist of the nonclassical K2P channels TREK-1 and TRAAK.
-
BMS-813160
BMS-813160 is the first dualCCR2/CCR5antagonist to enter Clinical development for cardiovascular.
-
XE-991
XE-991 is a potent, selective and orally active blocker of voltage-gated potassium channels Kv7 (KCNQ) that blocks KCNQ1, KCNQ2 and KCNQ2+KCNQ3 with Kd of 0.78, 0.7 and 0.6 uM, respectively.